drugset / Trial / NCT05184816
A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis
Phase 1
Recruiting
32 enrolled
Memorial Sloan Kettering Cancer Center
Center for Experimental Therapeutics · collabF.M. KIRBY FOUNDATION · collab
NaSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether deferoxamine (DFO) given intrathecally (directly into the CSF) is a safe treatment for people with leptomeningeal metastasis from solid tumor cancer. The researchers will test different doses of DFO to find the highest dose that causes few or mild side effects. When the dose is found, they will test it in future participants to see whether DFO is a safe and effective treatment for people with leptomeningeal metastasis from solid tumor malignancies. They are also doing this study to see how the body absorbs, distributes, gets rid of, and responds to DFO.
Timeline
- Start
- 2021-12-22
- Primary completion
- 2027-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deferoxamine | Other / unclassified | 10 mg | Intrathecal |
| Subject | Deferoxamine | Other / unclassified | 30 mg | Intrathecal |
| Subject | Deferoxamine | Other / unclassified | 60 mg | Intrathecal |
| Subject | Deferoxamine | Other / unclassified | 100 mg | Intrathecal |
| Subject | Deferoxamine | Other / unclassified | 150 mg | Intrathecal |
| Subject | Deferoxamine | Other / unclassified | 210 mg | Intrathecal |
| Subject | Deferoxamine | Other / unclassified | 280 mg | Intrathecal |
| Subject | Deferoxamine | Other / unclassified | 372 mg | Intrathecal |
| Subject | Deferoxamine | Other / unclassified | 495 mg | Intrathecal |